17 October 2017
News and Views
Links and Services
Mesalamine, but not sulfasalazine, reduces the risk of colorectal neoplasia in patients with inflammatory bowel disease, reports this month's Inflammatory Bowel Disease.
In some studies, 5-aminosalicylates as a class have been associated with protective effects again
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors